WSGR logoWSGR logo
Farah B. Gerdes
Partner
Technology Transactions
Boston

D617-598-7821

Download vCard
Open PDF
  • Experienced Intellectual Property Transactional Attorney

    Farah counsels clients with respect to the structuring and negotiation of a wide range of agreements, including strategic alliances, joint ventures, incubator structures, options, and build-to-buy arrangements.

  • A Focus on Scientific Clients

    Her clients are primarily based in the pharmaceutical, biotechnology, medical device, and diagnostic industries.

  • Regulatory Expertise

    Farah advises her life sciences clients on a variety of FDA regulatory and healthcare issues, in the context of their business transactions.

Farah Gerdes founded and leads the technology transactions practice in Wilson Sonsini Goodrich & Rosati's Boston office, where she focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions. She advises numerous domestic and international, public and private life sciences companies on business transactions related to the discovery, development, supply, and commercialization of life sciences products and technologies. She counsels her clients with respect to the structuring and negotiation of a wide range of agreements, including strategic alliances, joint ventures, incubator structures, options, and build-to-buy arrangements, each designed to maximize the value of their assets. In addition, Farah helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements. She works closely with her clients in setting strategic direction and structuring and negotiating mission-critical business arrangements.

As a complement to her transactional IP practice, Farah advises her life sciences clients on a variety of FDA regulatory and healthcare issues, in the context of their business transactions.

Experience

Farah Gerdes founded and leads the technology transactions practice in Wilson Sonsini Goodrich & Rosati's Boston office, where she focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions. She advises numerous domestic and international, public and private life sciences companies on business transactions related to the discovery, development, supply, and commercialization of life sciences products and technologies. She counsels her clients with respect to the structuring and negotiation of a wide range of agreements, including strategic alliances, joint ventures, incubator structures, options, and build-to-buy arrangements, each designed to maximize the value of their assets. In addition, Farah helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements. She works closely with her clients in setting strategic direction and structuring and negotiating mission-critical business arrangements.

As a complement to her transactional IP practice, Farah advises her life sciences clients on a variety of FDA regulatory and healthcare issues, in the context of their business transactions.

Focus Areas
Recent Insights
News Articles
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Learn More
Client Highlights
Wilson Sonsini Advises Proxima on $80 Million Seed Financing
On January 13, 2026, Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, announced an oversubscribed $80 million Seed financing.
Learn More
View All
Recent Events
WSGR Events
Navigating National Security Risks in Life Sciences
As geopolitical concerns create hurdles for cross-border collaboration in biotechnology and life sciences, maintaining visibility into evolving national security and trade requirements is critical for effective global partnering. Wilson Sonsini’s National Security and Trade team invites you to join a webinar exploring recent national security and trade law developments affecting life sciences companies, including how companies are navigating the resulting challenges.
Learn More
Affiliated Programs
L Suite (TechGC) Biotech GC Kickoff Dinner in Boston
On September 17, 2025, The L Suite (TechGC) is hosting our first-ever Biotech GC Kickoff Dinner in Boston, an invite-only evening bringing together CLOs and General Counsels from across the biotech ecosystem. The L Suite biotech community grows quickly, and this dinner is a chance for Boston legal leaders to gather in one room with their closest peers to talk openly about the challenges and opportunities shaping Biotech GCs today. Over a 3-course meal, we’ll dig into a conversation on the topic, “Partnering During Challenging Times: Getting the Deal Done in a Buyer’s Market.”
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.